India · Delayed Price · Currency is INR Alivus Life Sciences Company Description
Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India.
The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin.
It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies.
The company’s APIs are used in various therapeutic segments, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, and anti-infectives.
It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024.
The company was incorporated in 2011 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.
| Country | India |
| Founded | 2011 |
| Industry | Medicinal Chemicals and Botanical Products |
| Employees | 2,014 |
| CEO | Yasir Rawjee |
Contact Details
Address: OIA House Mumbai, Maharashtra 400099 India | |
| Phone | 91 22 6829 7979 |
| Website | alivus.com |
Stock Details
| Ticker Symbol | 543322 |
| Exchange | Bombay Stock Exchange |
| Fiscal Year | April - March |
| Reporting Currency | INR |
| SIC Code | 2833 |
Key Executives
| Name | Position |
|---|---|
| Yasir Rawjee | Chief Executive Officer |
| Tushar Mistry | Chief Financial Officer |